5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | NEUTRAL | NEUTRAL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 1.72▼ | 1.72▼ | 1.73▼ | 1.77▼ | 1.45▲ |
MA10 | 1.73▼ | 1.74▼ | 1.78▼ | 1.70▼ | 1.56▲ |
MA20 | 1.77▼ | 1.79▼ | 1.82▼ | 1.51▲ | 2.88▼ |
MA50 | 1.84▼ | 1.82▼ | 1.75▼ | 1.58▲ | 5.56▼ |
MA100 | 1.83▼ | 1.76▼ | 1.60▲ | 3.04▼ | N/A |
MA200 | 1.75▼ | 1.55▲ | 1.48▲ | 4.74▼ | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.005▼ | -0.012▼ | -0.024▼ | 0.055▲ | 0.137▲ |
RSI | 32.740▼ | 37.320▼ | 39.934▼ | 53.252▲ | 35.923▼ |
STOCH | 19.048▼ | 12.951▼ | 10.784▼ | 34.169 | 23.322 |
WILL %R | -92.857▼ | -94.118▼ | -95.000▼ | -67.424 | -68.290 |
CCI | -112.281▼ | -103.154▼ | -118.570▼ | 28.697 | -23.880 |
MA | $TRAW Price Crossed Below MA(7) | Set Alert |
Wednesday, June 04, 2025 07:00 PM
Traws Pharma, Inc. (NASDAQ: TRAW) has unveiled key clinical efficacy data for rigosertib, showcasing its potential as a treatment for squamous cell carcinoma (SCC) associated with recessive ...
|
Wednesday, June 04, 2025 10:41 AM
Eyenovia (NASDAQ: EYEN) Extends Betaliq Merger Talks its exclusivity period to finalize a merger with Betaliq, a clinical-stage glaucoma-focused company. The deal would unite Betaliq's Eyesol® ...
|
Wednesday, June 04, 2025 10:41 AM
Eyenovia (NASDAQ: EYEN) Extends Betaliq Merger Talks its exclusivity period to finalize a merger with Betaliq, a clinical-stage glaucoma-focused company. The deal would unite Betaliq's Eyesol® ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
13/06/25 | 1.79 | 1.79 | 1.67 | 1.69 | 152,044 |
12/06/25 | 1.84 | 1.8999 | 1.781 | 1.80 | 155,510 |
11/06/25 | 1.83 | 1.95 | 1.78 | 1.84 | 263,084 |
10/06/25 | 1.68 | 1.935 | 1.68 | 1.865 | 367,351 |
09/06/25 | 1.71 | 1.79 | 1.60 | 1.66 | 281,029 |
06/06/25 | 1.46 | 1.73 | 1.45 | 1.65 | 487,413 |
05/06/25 | 1.63 | 1.73 | 1.48 | 1.48 | 593,274 |
04/06/25 | 1.83 | 1.96 | 1.6501 | 1.72 | 1,736,006 |
03/06/25 | 2.53 | 2.58 | 1.81 | 1.87 | 62,770,662 |
02/06/25 | 1.42 | 1.45 | 1.33 | 1.42 | 137,571 |
|
|
||||
|
|
||||
|
|